Plant Biotechnology Market: Market Size & Forecast 2026

Plant biotechnology encompasses the application of genetic engineering, genome editing, molecular markers, and synthetic biology tools to improve crop traits such as yield, pest resistance, drought tolerance, and nutritional quality. The segment is projected to grow from roughly USD 51.7 billion in 2025 to approximately USD 76.8 billion by 2030, driven by large-scale adoption of genetically modified and gene-edited seed varieties in major row-crop markets. Broader biotechnology markets, including pharmaceuticals, industrial biotech, and bioagriculture combined, are estimated near USD 1.06 trillion in 2026 and expanding at approximately 12.86% per year, reflecting strong investment flows across life sciences sectors.

• •Plant biotechnology segment: ~USD 51.7 billion (2025) → ~USD 76.8 billion (2030), ~8.2% CAGR
• •Overall biotechnology market: ~USD 1.06 trillion (2026), growing at ~12.86% annually
• •Applications span transgenic crops, gene-edited varieties, biofortification, plant-made pharmaceuticals, and molecular farming

Rising global population, projected to approach 10 billion by 2050, is placing increasing pressure on agricultural systems to produce more output from constrained arable land, making yield-enhancing biotech traits a priority for growers and seed companies alike. Escalating climate volatility, including droughts, heatwaves, and shifting pest pressures, is accelerating adoption of stress-tolerant and input-efficient biotech crop varieties. Concurrently, tightening environmental regulations and consumer demand for lower-pesticide, sustainable farming practices are driving regulatory frameworks in several regions toward faster approval pathways for gene-edited crops.

• •Global food security imperatives and rising demand for protein-intensive diets drive demand for higher-yield, climate-resilient crop varieties
• •Drought, heat stress, and shifting pest pressures accelerate adoption of stress-tolerant and resource-efficient biotech traits
• •Regulatory modernization and sustainability mandates across multiple jurisdictions are opening approval pathways for new plant biotech products

The plant biotechnology market is segmented across technology platforms, including transgenics, genome editing (e.g., CRISPR-based tools), genomic selection using molecular markers, tissue culture and regeneration systems, and synthetic biology approaches, each serving different crop and trait development needs. Geographically, North America leads in adoption rates and commercial cultivation of biotech crops, while Europe operates under a more restrictive regulatory environment for transgenic products, though gene-edited varieties are gaining traction. Asia-Pacific, led by China and India, represents the fastest-growing regional market due to large domestic agricultural sectors and increasing government support for agricultural modernization.

• •Technology segmentation: transgenics, genome editing, molecular marker-assisted breeding, tissue culture, synthetic biology
• •Crop-type segmentation: major row crops (corn, soy, cotton, canola), fruits and vegetables, cereals, and specialty crops
• •North America holds the largest share, followed by Europe and Asia-Pacific, with Latin America as a key emerging cultivation zone

Who are the notable companies in the industry?

The plant biotechnology market exhibits a moderately consolidated structure at the seed trait development level, where a handful of large integrated players control proprietary gene and trait libraries, regulatory dossiers, and distribution networks for major row crops. Leading participants include Bayer AG, whose Crop Science division is channeling investment into cell and gene-based technologies to strengthen plant resilience against drought, pests, and soil degradation, and Corteva Agriscience, which is advancing biological inputs through offerings such as the Lumidapt Valta LS seed treatment. BASF SE contributes expertise across crop protection and agricultural solutions, complementing the trait pipelines of the seed majors. Syngenta AG operates as another integrated developer of biotech seeds and crop protection technologies, while FMC Corporation and UPL are positioned within the broader crop input ecosystem supporting biological and conventional solutions. Sumitomo Chemical and Nufarm extend the competitive field through their respective agrochemical and seed-adjacent portfolios. Below this tier, a fragmented layer of mid-sized and specialty producers focuses on niche crop segments, novel traits, or regional markets, often licensing foundational technologies from larger entities or pursuing proprietary gene-editing platforms. The value chain spans upstream technology providers supplying gene-editing tools and bioinformatics platforms, midstream trait developers conducting research and field trials, and downstream seed distributors and growers who commercialize the final products.

• •Market structure: dual-tier with consolidated major trait developers and a fragmented specialist/niche segment
• •Technology routes: transgenic introgression, nuclease-based genome editing, RNAi-mediated trait silencing, marker-assisted selection, and synthetic pathway engineering
• •Production capacity and R&D hubs are concentrated in North America and Europe, with growing infrastructure in Brazil, Argentina, China, and India

What are the recent trends and outlook?

Gene editing technologies, particularly site-directed nucleases, are reshaping the regulatory and commercial landscape by enabling precise trait modifications without foreign DNA insertion, potentially accelerating approval timelines and market acceptance compared with first-generation transgenic approaches. The convergence of plant biotechnology with digital agriculture platforms, including AI-driven trait prediction and field phenotyping, is creating more efficient R&D pipelines and enabling trait stacking at scale. Molecular farming, the production of high-value pharmaceuticals, enzymes, and industrial proteins in plant biofactories, represents a promising adjacent growth area, while sustainability certifications and carbon-market frameworks are beginning to incorporate biotech crop adoption as a qualifying practice.

• •CRISPR and next-generation gene editing tools are driving a wave of new trait development with potentially streamlined regulatory pathways in multiple jurisdictions
• •Integration with AI-powered breeding platforms and digital phenotyping is shortening R&D cycles and reducing product development costs
• •Molecular farming and plant-based bio-manufacturing of pharmaceuticals and industrial proteins is emerging as a high-value adjacent application